Market research
2K4.F PhaseBio Pharmaceuticals, Inc
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 16.5
- Dividend yield
- 0.0%
- Beta
- 2.38
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 4M
- P/E ratio
- Not available
- Analyst target
- 16.5
- Dividend yield
- 0.0%
- Beta
- 2.38
About
About PhaseBio Pharmaceuticals, Inc
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 2K4.F discussion.
5 years, 4 months ago
PhaseBio Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 1.5% below its 200 day moving average.
From a valuation standpoint, the stock is 76.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 308.8.
PhaseBio Pharmaceuticals, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 168.1% to $-30M since the same quarter in the previous year.
Finally, its free cash flow grew by 9.7% to $-11M since the same quarter in the previous year.
Based on the above factors, PhaseBio Pharmaceuticals, Inc gets an overall score of 2/5.